Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape

Durán‐Lobato, Matilde; López-Estévez, Ana M.; Cordeiro, Ana Sara; Dacoba, Tamara G.; Crecente‐Campo, José; Torres, Dolores; Alonso, María José

doi:10.1016/j.addr.2021.113899

Cited by 45 publications

(29 citation statements)

References 347 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a substitute for these biological vectors, NPs have higher controllability and safety. Protein subunit vaccines tend to be neutralized by antibodies inherent in the mucosal layer, or some proteases present in the nose can also cause their immunogenicity to be reduced [ 113 ]. Some NPs, such as PLGA, liposomes or nanoparticle assemblies, prevent antigen neutralization and enhance cellular uptake.…”

Section: Why Choose Nasal Nanovaccine In Sars-cov-2?mentioning

confidence: 99%

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

et al. 2022

View full text Add to dashboard Cite

COVID-19 is still prevalent around the globe. Although some SARS-CoV-2 vaccines have been distributed to the population, the shortcomings of vaccines and the continuous emergence of SARS-CoV-2 mutant virus strains are a cause for concern. Thus, it is vital to continue to improve vaccines and vaccine delivery methods. One option is nasal vaccination, which is more convenient than injections and does not require a syringe. Additionally, stronger mucosal immunity is produced under nasal vaccination. The easy accessibility of the intranasal route is more advantageous than injection in the context of the COVID-19 pandemic. Nanoparticles have been proven to be suitable delivery vehicles and adjuvants, and different NPs have different advantages. The shortcomings of the SARS-CoV-2 vaccine may be compensated by selecting or modifying different nanoparticles. It travels along the digestive tract to the intestine, where it is presented by GALT, tissue-resident immune cells, and gastrointestinal lymph nodes. Nasal nanovaccines are easy to use, safe, multifunctional, and can be distributed quickly, demonstrating strong prospects as a vaccination method for SARS-CoV-2, SARS-CoV-2 variants, or SARS-CoV-n.

show abstract

Section: Why Choose Nasal Nanovaccine In Sars-cov-2?mentioning

confidence: 99%

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Indeed, nanocarriers can facilitate the targeting and/or sustained release of antigens or adjuvants to APCs [152]. Nowadays, it is clear that nanovaccines represent a key milestone in the prevention of classical and emerging diseases [153].…”

Section: Nanoparticles In Vaccine Formulationsmentioning

confidence: 99%

Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines

Mitarotonda¹,

Giorgi²,

Eufrásio-da-Silva³

et al. 2022

Biomaterials Advances

View full text Add to dashboard Cite

“…Another interesting strategy that can be used for blocking TFs are antibodies as they can virtually target any given oncoprotein. Whilst the use of antibodies was inconceivable in the past for targeting intracellular targets due to their inability to cross biological membranes, it seems plausible now with the use of nanotechnology [ 154 ]. Deng et al delivered monoclonal antibodies anti-S100A4 in the cytoplasm using liposomes.…”

Section: Future Perspectivesmentioning

confidence: 99%

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

Marqués

Sorolla

Urdanibia

et al. 2022

Cancers

View full text Add to dashboard Cite

Breast cancer (BC) is the most diagnosed cancer worldwide and one of the main causes of cancer deaths. BC is a heterogeneous disease composed of different BC intrinsic subtypes such as triple-negative BC (TNBC), which is one of the most aggressive subtypes and which lacks a targeted therapy. Recent comprehensive analyses across cell types and cancer types have outlined a vast network of protein–protein associations between transcription factors (TFs). Not surprisingly, protein–protein networks central to oncogenesis and disease progression are highly altered during TNBC pathogenesis and are responsible for the activation of oncogenic programs, such as uncontrollable proliferation, epithelial-to-mesenchymal transition (EMT) and stemness. From the therapeutic viewpoint, inhibiting the interactions between TFs represents a very significant challenge, as the contact surfaces of TFs are relatively large and featureless. However, promising tools have emerged to offer a solution to the targeting problem. At the clinical level, some TF possess diagnostic and prognostic value in TNBC. In this review, we outline the recent advances in TFs relevant to TNBC growth and progression. Moreover, we highlight different targeting approaches to inhibit these TFs. Furthermore, the validity of such TFs as clinical biomarkers has been explored. Finally, we discuss how research is likely to evolve in the field.

show abstract

Nanotechnologies for the delivery of biologicals: Historical perspective and current landscape

Cited by 45 publications

References 347 publications

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19

Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

Contact Info

Product

Resources

About